carbon monoxide has been researched along with Diffuse Parenchymal Lung Disease in 80 studies
Carbon Monoxide: Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed)
carbon monoxide : A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The potential of CO-releasing molecules (CORMs), substances that release CO (Carbon monoxide) within animal tissues, for treating paraquat-induced ROS generation and inflammation is investigated here." | 8.02 | The effects of carbon monoxide releasing molecules on paraquat-induced pulmonary interstitial inflammation and fibrosis. ( Chang, CY; Cheng, CH; Chiu, HY; Chuu, JJ; Huang, KC; Li, JC; Lin, LS; Wang, SM; Yeh, CH, 2021) |
| "There was increased mortality in interstitial lung disease‒PH as compared with chronic obstructive pulmonary disease‒PH, but PH severity based on the WHO classification did not alter survival." | 5.51 | Survival in pulmonary hypertension due to chronic lung disease: Influence of low diffusion capacity of the lungs for carbon monoxide. ( Archer, SL; Misialek, JR; Prins, KW; Pritzker, M; Rose, L; Thenappan, T; Weir, EK, 2019) |
| " The potential of CO-releasing molecules (CORMs), substances that release CO (Carbon monoxide) within animal tissues, for treating paraquat-induced ROS generation and inflammation is investigated here." | 4.02 | The effects of carbon monoxide releasing molecules on paraquat-induced pulmonary interstitial inflammation and fibrosis. ( Chang, CY; Cheng, CH; Chiu, HY; Chuu, JJ; Huang, KC; Li, JC; Lin, LS; Wang, SM; Yeh, CH, 2021) |
| "1% during follow-up, and it was significantly associated to digital ulcers, interstitial lung disease, reduction of diffusion lung of carbon monoxide <75%, teleangectasias and melanodermia, while sicca syndrome and arthralgias were associated to normal/nonspecific pattern." | 3.81 | Prevalence and evolution of scleroderma pattern at nailfold videocapillaroscopy in systemic sclerosis patients: Clinical and prognostic implications. ( Campomori, F; Colaci, M; Ferri, C; Ghizzoni, C; Giuggioli, D; Manfredi, A; Sebastiani, M, 2015) |
| "In systemic sclerosis (SSc), impaired diffusing capacity for carbon monoxide (DLCO) can indicate interstitial lung disease (ILD), pulmonary hypertension (PH), and/or other disease manifestations, including anemia." | 3.79 | Comparison of different measures of diffusing capacity for carbon monoxide (DLCO) in systemic sclerosis. ( Assayag, D; Baron, M; Caron, M; Fox, BD; Gaudreau-Taillefer, R; Hirsch, A; Hudson, M; Rudski, L; Steele, R; Tatibouet, S, 2013) |
| "Diffusion capacity for carbon monoxide of the lung (DLCO) before-and-after exercise test and 5 routine pulmonary function tests were conducted in 16 patients with diffuse pulmonary fibrosis (DPF), 19 patients with interstitial pneumonia (IP), 17 patients with COPD, and 22 normal subjects." | 3.69 | [Diagnostic value of exercise diffusion capacity test on diffuse pulmonary fibrosis]. ( He, T; Luo, Y; Yuan, Y; Zeng, J, 1996) |
| "Extent of systemic sclerosis (SSc)-related interstitial lung disease (ILD) assessed from thoracic high-resolution CT (HRCT) predicts disease course, mortality and treatment response." | 2.82 | Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. ( Clements, P; Elashoff, R; Furst, D; Goldin, J; Khanna, D; Kim, HJ; Kleerup, E; Roth, MD; Tashkin, DP; Tseng, CH; Volkmann, ER, 2016) |
| "Currently, therapy for interstitial lung disease in patients with systemic sclerosis is unsatisfactory." | 2.74 | High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study. ( Bambery, P; Sharma, A; Sharma, S; Suryanaryana, BS; Wanchu, A, 2009) |
| "Interstitial lung disease is a rare manifestation of NPD." | 2.41 | Pulmonary involvement in Niemann-Pick disease: case report and literature review. ( Minai, OA; Stoller, JK; Sullivan, EJ, 2000) |
| "Pulmonary function changes in interstitial lung disease are characterized by loss of lung volume, increase in ratio of forced expiratory volume in 1 second to forced vital capacity, and decrease in carbon monoxide diffusion capacity." | 2.39 | Pulmonary physiology in interstitial lung disease: recent developments in diagnostic and prognostic implications. ( Baydur, A, 1996) |
| "Of the entire cohort (n = 243), systemic sclerosis (SSc)-associated ILD (n = 88, 36%), interstitial pneumonia with autoimmune features (IPAF, n = 56, 23%), rheumatoid arthritis (RA)-associated ILD (n = 42, 17%), and idiopathic inflammatory myopathy (IIM)-associated ILD (n = 26, 11%) were the most common phenotypes." | 1.51 | Clinical Characteristics and Natural History of Autoimmune Forms of Interstitial Lung Disease: A Single-Center Experience. ( Chartrand, S; Fischer, A; Lee, JS; Stanchev, L; Swigris, JJ, 2019) |
| "There was increased mortality in interstitial lung disease‒PH as compared with chronic obstructive pulmonary disease‒PH, but PH severity based on the WHO classification did not alter survival." | 1.51 | Survival in pulmonary hypertension due to chronic lung disease: Influence of low diffusion capacity of the lungs for carbon monoxide. ( Archer, SL; Misialek, JR; Prins, KW; Pritzker, M; Rose, L; Thenappan, T; Weir, EK, 2019) |
| "This study aimed to investigate the disease progression and mortality of patients with CTD-ILD and idiopathic interstitial pneumonias (IIP) including idiopathic pulmonary fibrosis (IPF) and idiopathic nonspecific interstitial pneumonia and the prognostic impact of the radiological UIP pattern on both disease groups." | 1.51 | Comparison of clinical courses and mortality of connective tissue disease-associated interstitial pneumonias and chronic fibrosing idiopathic interstitial pneumonias. ( Bitik, B; Erbaş, G; Haznedaroğlu, Ş; Köktürk, N; Türk, M; Türktaş, H; Yıldırım, F, 2019) |
| "Pulmonary emphysema combined with systemic sclerosis (SSc)-associated interstitial lung disease (ILD) occurs more often in smokers but also in never-smokers." | 1.48 | Emphysematous change with scleroderma-associated interstitial lung disease: the potential contribution of vasculopathy? ( Baba, T; Ikeda, S; Iso, S; Iwasawa, T; Kitamura, H; Kuwano, K; Ogura, T; Okudela, K; Sekine, A; Takemura, T; Yamakawa, H; Yamanaka, Y, 2018) |
| "Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is associated with significant morbidity and mortality." | 1.46 | The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease. ( Cerri, S; Collard, HR; Elicker, BM; Gross, AJ; Hu, X; Jones, KD; Kim, DS; King, TE; Lee, BY; Lee, JS; Ley, B; Manfredi, A; Morisset, J; Ryu, JH; Sebastiani, M; Tonelli, R; Vittinghoff, E; Wolters, PJ, 2017) |
| "Systemic sclerosis-related interstitial lung disease (SSc-ILD) is the leading cause of death in SSc." | 1.46 | Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease. ( Béhal, H; Duhamel, A; Faivre, JB; Hachulla, AL; Hachulla, E; Hatron, PY; Lambert, M; Launay, D; Le Gouellec, N; Matran, R; Morell-Dubois, S; Perez, T; Remy-Jardin, M; Sobanski, V, 2017) |
| "Unclassifiable-interstitial lung disease (uILD) represents a heterogeneous collection of pathologies encompassing those fibrosing lung diseases which do not fulfill current diagnostic criteria." | 1.46 | Unclassifiable-interstitial lung disease: Outcome prediction using CT and functional indices. ( Bartholmai, BJ; Brun, AL; Egashira, R; Hansell, DM; Jacob, J; Karwoski, R; Kokosi, M; Nair, A; Nicholson, AG; Rajagopalan, S; Walsh, SLF; Wells, AU, 2017) |
| "The test time of re-breathing in the COPD group (106 ± 5) s was significant longer than that of the ILD group (73 ± 4) s and the control group (79 ± 5) s (F = 11." | 1.39 | [Single-breath and rebreathing methods for measurement of pulmonary diffusing function: a comparative study]. ( An, JY; Gao, Y; Guan, WJ; Jiang, CY; Liu, QX; Liu, WT; Xie, YQ; Yu, XX; Zheng, JP, 2013) |
| "TwPmo and TwPdi were lower in interstitial lung disease patients (mean±sd TwPmo 0." | 1.39 | Respiratory muscle function in interstitial lung disease. ( Kabitz, HJ; Müller-Quernheim, J; Schlager, D; Walker, DJ; Walterspacher, S; Windisch, W, 2013) |
| "In very severe interstitial lung disease associated with connective tissue disease (CTD-ILD), progressing despite maximal conventional immunosuppression, there is no effective medical rescue therapy." | 1.38 | Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. ( Denton, CP; Hansell, DM; Keir, GJ; Maher, TM; Ong, VH; Renzoni, EA; Singh, S; Wells, AU, 2012) |
| "More than 80% of patients with systemic sclerosis (SSc) develop lung involvement, most commonly interstitial pneumonia (IP)." | 1.38 | The pulmonary fibrosis-associated MUC5B promoter polymorphism does not influence the development of interstitial pneumonia in systemic sclerosis. ( Carns, M; Fingerlin, TE; Hinchcliff, ME; Murphy, E; Peljto, AL; Podlusky, S; Schwartz, DA; Schwarz, M; Steele, MP; Varga, J, 2012) |
| "Pulmonary hypertension (PH) complicating systemic sclerosis (SSc)-related interstitial lung disease (ILD) is usually associated with a poor prognosis." | 1.37 | Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. ( Allanore, Y; Berezne, A; Bletry, O; Clerson, P; Cottin, V; Couderc, LJ; Hachulla, E; Hatron, PY; Humbert, M; Launay, D; Le Pavec, J; Mouthon, L; Yaici, A, 2011) |
| "Different interstitial lung diseases may show distinct lymphocyte activation profiles." | 1.36 | T-cell activation profiles in different granulomatous interstitial lung diseases--a role for CD8+CD28(null) cells? ( Claessen, AM; Grutters, JC; Heron, M; van den Bosch, JM, 2010) |
| "Sarcoidosis is a systemic granulomatous disease with predominant manifestation in the lungs, often presenting as interstitial lung disease." | 1.36 | Impaired lung compliance and DL,CO but no restrictive ventilatory defect in sarcoidosis. ( Boros, PW; Borsboom, GJ; Enright, PL; Hyatt, RE; Quanjer, PH; Wesolowski, SP, 2010) |
| "Pulmonary fibrosis is defined by an overgrowth of fibroblasts and extracellular matrix deposition, and results in respiratory dysfunction that is often fatal." | 1.36 | MRP14 is elevated in the bronchoalveolar lavage fluid of fibrosing interstitial lung diseases. ( Grutters, JC; Kazemier, KM; Korthagen, NM; Nagtegaal, MM; van den Bosch, JM; van Moorsel, CH, 2010) |
| "Among the most common are interstitial lung disease (ILD) and bronchiectasis." | 1.35 | Clinical and high resolution computed tomography characteristics of patients with rheumatoid arthritis lung disease. ( Abdul Manap, R; Azhar Shah, S; Mohd Noor, N; Mohd Shahrir, MS; Shahid, MS; Shahizon Azura, AM, 2009) |
| "The 14 patients without emphysema had interstitial lung disease, pulmonary vascular disease, and other isolated findings." | 1.34 | Retrospective study of pulmonary function tests in patients presenting with isolated reduction in single-breath diffusion capacity: implications for the diagnosis of combined obstructive and restrictive lung disease. ( Aduen, JF; Alvarez, F; Biewend, M; Jolles, HI; Keller, CA; Mobin, SI; Venegas, C; Zisman, DA, 2007) |
| "Age and the presence of interstitial lung disease (ILD) were associated with more frequent occurrence of TG > 23 and > 33 mmHg initially and at follow-up, but were not associated with progression rate." | 1.33 | Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001. ( Akesson, A; Ekman, R; Eskilsson, J; Hesselstrand, R; Isaksson, A; Ohlin, AK; Scheja, A, 2005) |
| "Diffuse parenchymal lung disease is associated with a high risk of mortality despite early referral and listing for lung transplantation." | 1.33 | Exercise testing determines survival in patients with diffuse parenchymal lung disease evaluated for lung transplantation. ( Arcasoy, SM; Bartels, MN; Kawut, SM; O'Shea, MK; Sonett, JR; Wilt, JS, 2005) |
| " In three patients the pulmonary disorder seems to have been caused by a cell-mediated immunological side effect in the form of interstitial pneumonitis." | 1.32 | Pulmonary side effects of interferon-alpha therapy in patients with hematological malignancies. ( Anderson, P; Höglund, M; Rödjer, S, 2003) |
| "Amiodarone is a useful drug for the treatment of life-threatening cardiac arrhythmias." | 1.31 | Serum KL-6 as a possible marker for amiodarone-induced pulmonary toxicity. ( Kawahara, Y; Matsushima, T; Miyashita, N; Nakajima, M; Niki, Y; Yoshida, K, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (3.75) | 18.2507 |
| 2000's | 21 (26.25) | 29.6817 |
| 2010's | 44 (55.00) | 24.3611 |
| 2020's | 12 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, K | 1 |
| Zou, X | 1 |
| Ma, Z | 1 |
| Liu, X | 1 |
| Qiu, C | 1 |
| Xie, L | 1 |
| Lin, Z | 1 |
| Li, S | 1 |
| Wu, Y | 1 |
| Ibrahim, NH | 1 |
| Fawzy, IM | 1 |
| Gouda, TM | 1 |
| El Sayed, RAH | 1 |
| Morsi, MH | 1 |
| Sabry, ASM | 1 |
| Hashaad, NI | 1 |
| Şenkal, N | 1 |
| Kıyan, E | 1 |
| Demir, AA | 1 |
| Yalçınkaya, Y | 1 |
| Gül, A | 1 |
| İnanç, M | 1 |
| Öçal, ML | 1 |
| Esen, BA | 1 |
| Axtell, AL | 1 |
| David, EA | 1 |
| Block, MI | 1 |
| Parsons, N | 1 |
| Habib, R | 1 |
| Muniappan, A | 1 |
| Taytard, J | 1 |
| Boizeau, P | 1 |
| Alberti, C | 1 |
| Beydon, N | 1 |
| Chartrand, S | 2 |
| Lee, JS | 4 |
| Swigris, JJ | 3 |
| Stanchev, L | 2 |
| Fischer, A | 3 |
| Ciaffi, J | 1 |
| van Leeuwen, NM | 1 |
| Liem, SIE | 1 |
| Ninaber, MK | 1 |
| Huizinga, TWJ | 1 |
| de Vries-Bouwstra, JK | 1 |
| Distler, O | 1 |
| Assassi, S | 1 |
| Cottin, V | 2 |
| Cutolo, M | 1 |
| Danoff, SK | 1 |
| Denton, CP | 2 |
| Distler, JHW | 2 |
| Hoffmann-Vold, AM | 1 |
| Johnson, SR | 1 |
| Müller Ladner, U | 1 |
| Smith, V | 1 |
| Volkmann, ER | 3 |
| Maher, TM | 2 |
| Sekine, A | 2 |
| Wasamoto, S | 1 |
| Hagiwara, E | 1 |
| Yamakawa, H | 2 |
| Ikeda, S | 2 |
| Okabayashi, H | 1 |
| Oda, T | 1 |
| Okuda, R | 1 |
| Kitamura, H | 2 |
| Baba, T | 2 |
| Komatsu, S | 1 |
| Ogura, T | 2 |
| Shen, YW | 1 |
| Zhang, YM | 1 |
| Huang, ZG | 1 |
| Wang, GC | 1 |
| Peng, QL | 1 |
| Štorkánová, H | 1 |
| Oreská, S | 1 |
| Špiritović, M | 1 |
| Heřmánková, B | 1 |
| Bubová, K | 1 |
| Komarc, M | 1 |
| Pavelka, K | 1 |
| Vencovský, J | 1 |
| Šenolt, L | 1 |
| Bečvář, R | 1 |
| Tomčík, M | 1 |
| Wardyn, PM | 1 |
| de Broucker, V | 1 |
| Chenivesse, C | 1 |
| Sobaszek, A | 1 |
| Van Bulck, R | 1 |
| Perez, T | 3 |
| Edmé, JL | 1 |
| Hulo, S | 1 |
| Huang, KC | 1 |
| Li, JC | 1 |
| Wang, SM | 1 |
| Cheng, CH | 1 |
| Yeh, CH | 1 |
| Lin, LS | 1 |
| Chiu, HY | 1 |
| Chang, CY | 1 |
| Chuu, JJ | 1 |
| Pitsidianakis, G | 1 |
| Vassalou, EE | 1 |
| Vasarmidi, E | 1 |
| Bolaki, M | 1 |
| Klontzas, ME | 1 |
| Xirouchaki, N | 1 |
| Georgopoulos, D | 1 |
| Karantanas, AH | 1 |
| Tzanakis, N | 1 |
| Antoniou, KM | 1 |
| Layton, AM | 1 |
| Armstrong, HF | 1 |
| Kim, HP | 1 |
| Meza, KS | 1 |
| D'Ovidio, F | 1 |
| Arcasoy, SM | 2 |
| Natalini, JG | 1 |
| Morisset, J | 2 |
| Elicker, BM | 2 |
| Jones, KD | 2 |
| Collard, HR | 2 |
| Vittinghoff, E | 1 |
| Lee, BY | 1 |
| Tonelli, R | 1 |
| Hu, X | 1 |
| Ryu, JH | 1 |
| Cerri, S | 2 |
| Manfredi, A | 3 |
| Sebastiani, M | 3 |
| Gross, AJ | 1 |
| Ley, B | 1 |
| Wolters, PJ | 1 |
| King, TE | 1 |
| Kim, DS | 1 |
| Ungprasert, P | 1 |
| Wilton, KM | 1 |
| Ernste, FC | 1 |
| Kalra, S | 1 |
| Crowson, CS | 1 |
| Rajagopalan, S | 2 |
| Bartholmai, BJ | 3 |
| Arcadu, A | 1 |
| Byrne, SC | 1 |
| Pirina, P | 1 |
| Hartman, TE | 1 |
| Moua, T | 1 |
| Le Gouellec, N | 1 |
| Duhamel, A | 1 |
| Hachulla, AL | 1 |
| Sobanski, V | 2 |
| Faivre, JB | 1 |
| Morell-Dubois, S | 3 |
| Lambert, M | 3 |
| Hatron, PY | 4 |
| Hachulla, E | 4 |
| Béhal, H | 1 |
| Matran, R | 2 |
| Launay, D | 4 |
| Remy-Jardin, M | 3 |
| Du Plessis, JP | 1 |
| Fernandes, S | 1 |
| Jamal, R | 1 |
| Camp, P | 1 |
| Johannson, K | 1 |
| Schaeffer, M | 1 |
| Wilcox, PG | 1 |
| Guenette, JA | 1 |
| Ryerson, CJ | 1 |
| Jacob, J | 1 |
| Egashira, R | 1 |
| Brun, AL | 1 |
| Kokosi, M | 1 |
| Nair, A | 1 |
| Walsh, SLF | 1 |
| Karwoski, R | 1 |
| Nicholson, AG | 1 |
| Hansell, DM | 2 |
| Wells, AU | 2 |
| Hashimoto, N | 1 |
| Ando, A | 1 |
| Iwano, S | 1 |
| Sakamoto, K | 1 |
| Okachi, S | 1 |
| Matsuzaki, A | 1 |
| Okada, Y | 1 |
| Wakai, K | 1 |
| Yokoi, K | 1 |
| Hasegawa, Y | 1 |
| Takemura, T | 1 |
| Iwasawa, T | 1 |
| Yamanaka, Y | 1 |
| Iso, S | 1 |
| Okudela, K | 1 |
| Kuwano, K | 1 |
| Barratt, SL | 1 |
| Shaw, J | 1 |
| Jones, R | 1 |
| Bibby, A | 1 |
| Adamali, H | 1 |
| Mustfa, N | 1 |
| Cliff, I | 1 |
| Stone, H | 1 |
| Chaudhuri, N | 1 |
| Caetano, J | 1 |
| Paula, FS | 1 |
| Amaral, M | 1 |
| Oliveira, S | 1 |
| Alves, JD | 1 |
| Öztürk, A | 1 |
| Kayacan, O | 1 |
| Rose, L | 1 |
| Prins, KW | 1 |
| Archer, SL | 1 |
| Pritzker, M | 1 |
| Weir, EK | 1 |
| Misialek, JR | 1 |
| Thenappan, T | 1 |
| Tashkin, DP | 2 |
| Sim, M | 1 |
| Li, N | 1 |
| Goldmuntz, E | 1 |
| Keyes-Elstein, L | 1 |
| Pinckney, A | 1 |
| Furst, DE | 1 |
| Clements, PJ | 1 |
| Khanna, D | 2 |
| Steen, V | 1 |
| Schraufnagel, DE | 1 |
| Arami, S | 1 |
| Hsu, V | 1 |
| Roth, MD | 2 |
| Elashoff, RM | 1 |
| Sullivan, KM | 1 |
| Yıldırım, F | 1 |
| Türk, M | 1 |
| Bitik, B | 1 |
| Erbaş, G | 1 |
| Köktürk, N | 1 |
| Haznedaroğlu, Ş | 1 |
| Türktaş, H | 1 |
| Ghang, B | 1 |
| Lee, J | 1 |
| Chan Kwon, O | 1 |
| Ahn, SM | 1 |
| Oh, JS | 1 |
| Hong, S | 1 |
| Kim, YG | 1 |
| Yoo, B | 1 |
| Jeong, WS | 1 |
| Kim, J | 1 |
| Lee, CK | 1 |
| Hudson, M | 1 |
| Assayag, D | 1 |
| Caron, M | 1 |
| Fox, BD | 1 |
| Hirsch, A | 1 |
| Steele, R | 1 |
| Gaudreau-Taillefer, R | 1 |
| Tatibouet, S | 1 |
| Rudski, L | 1 |
| Baron, M | 1 |
| Someya, F | 1 |
| Mugii, N | 1 |
| Hasegawa, M | 1 |
| Yahata, T | 1 |
| Nakagawa, T | 1 |
| Sivova, N | 1 |
| Wémeau-Stervinou, L | 1 |
| De Groote, P | 2 |
| Denis, G | 1 |
| Lamblin, N | 1 |
| Fertin, M | 1 |
| Lefevre, G | 1 |
| Le Rouzic, O | 1 |
| Wallaert, B | 1 |
| Liu, QX | 1 |
| Zheng, JP | 1 |
| Xie, YQ | 1 |
| Guan, WJ | 1 |
| Jiang, CY | 1 |
| An, JY | 1 |
| Yu, XX | 1 |
| Liu, WT | 1 |
| Gao, Y | 1 |
| Tseng, CH | 1 |
| Kim, HJ | 1 |
| Goldin, J | 1 |
| Clements, P | 1 |
| Furst, D | 1 |
| Kleerup, E | 1 |
| Elashoff, R | 1 |
| Ghizzoni, C | 1 |
| Campomori, F | 1 |
| Colaci, M | 2 |
| Giuggioli, D | 2 |
| Ferri, C | 2 |
| Pastre, J | 1 |
| Plantier, L | 1 |
| Planes, C | 1 |
| Borie, R | 1 |
| Nunes, H | 1 |
| Delclaux, C | 1 |
| Israël-Biet, D | 1 |
| Legnani, D | 1 |
| Rizzi, M | 1 |
| Sarzi-Puttini, P | 1 |
| Cristiano, A | 1 |
| La Spina, T | 1 |
| Frassanito, F | 1 |
| Airoldi, A | 1 |
| Atzeni, F | 1 |
| Go, DJ | 1 |
| Lee, EY | 1 |
| Lee, EB | 1 |
| Song, YW | 1 |
| Konig, MF | 1 |
| Park, JK | 1 |
| Lumetti, F | 1 |
| Luppi, F | 1 |
| Enright Md, P | 1 |
| Pingel, S | 1 |
| Passon, SG | 1 |
| Pausewang, KS | 1 |
| Blatzheim, AK | 1 |
| Pizarro, C | 1 |
| Tuleta, I | 1 |
| Gliem, M | 1 |
| Charbel Issa, P | 1 |
| Schahab, N | 1 |
| Nickenig, G | 1 |
| Skowasch, D | 1 |
| Schaefer, CA | 1 |
| Brown, KK | 1 |
| Callahan, SJ | 1 |
| Xia, M | 1 |
| Murray, S | 1 |
| Flaherty, KR | 1 |
| Shin, KM | 1 |
| Lee, KS | 1 |
| Chung, MP | 1 |
| Han, J | 1 |
| Bae, YA | 1 |
| Kim, TS | 1 |
| Chung, MJ | 1 |
| Hegewald, MJ | 1 |
| Heron, M | 1 |
| Claessen, AM | 1 |
| Grutters, JC | 3 |
| van den Bosch, JM | 2 |
| Funauchi, M | 1 |
| Kishimoto, K | 1 |
| Kinoshita, K | 1 |
| Mohd Noor, N | 1 |
| Mohd Shahrir, MS | 1 |
| Shahid, MS | 1 |
| Abdul Manap, R | 1 |
| Shahizon Azura, AM | 1 |
| Azhar Shah, S | 1 |
| Wanchu, A | 1 |
| Suryanaryana, BS | 1 |
| Sharma, S | 1 |
| Sharma, A | 1 |
| Bambery, P | 1 |
| Boros, PW | 1 |
| Enright, PL | 2 |
| Quanjer, PH | 1 |
| Borsboom, GJ | 1 |
| Wesolowski, SP | 1 |
| Hyatt, RE | 1 |
| Korthagen, NM | 1 |
| Nagtegaal, MM | 1 |
| van Moorsel, CH | 1 |
| Kazemier, KM | 1 |
| Humbert, M | 1 |
| Berezne, A | 1 |
| Allanore, Y | 1 |
| Couderc, LJ | 1 |
| Bletry, O | 1 |
| Yaici, A | 1 |
| Mouthon, L | 3 |
| Le Pavec, J | 1 |
| Clerson, P | 1 |
| Trad, S | 1 |
| Huong, du LT | 1 |
| Frances, C | 1 |
| Wechsler, B | 1 |
| Cacoub, P | 1 |
| Costedoat, N | 1 |
| Haroche, J | 1 |
| Piette, JC | 1 |
| Hanslik, T | 1 |
| Amoura, Z | 1 |
| Aozasa, N | 1 |
| Asano, Y | 1 |
| Akamata, K | 1 |
| Noda, S | 1 |
| Masui, Y | 1 |
| Tamaki, Z | 1 |
| Tada, Y | 1 |
| Sugaya, M | 1 |
| Kadono, T | 1 |
| Sato, S | 1 |
| Keir, GJ | 1 |
| Ong, VH | 1 |
| Singh, S | 1 |
| Renzoni, EA | 1 |
| Pernot, J | 1 |
| Puzenat, E | 1 |
| Magy-Bertrand, N | 1 |
| Manzoni, P | 1 |
| Gondouin, A | 1 |
| Bourdin, H | 1 |
| Simon-Rigaud, ML | 1 |
| Regnard, J | 1 |
| Degano, B | 1 |
| Peljto, AL | 1 |
| Steele, MP | 1 |
| Fingerlin, TE | 1 |
| Hinchcliff, ME | 1 |
| Murphy, E | 1 |
| Podlusky, S | 1 |
| Carns, M | 1 |
| Schwarz, M | 1 |
| Varga, J | 1 |
| Schwartz, DA | 1 |
| Walterspacher, S | 1 |
| Schlager, D | 1 |
| Walker, DJ | 1 |
| Müller-Quernheim, J | 1 |
| Windisch, W | 1 |
| Kabitz, HJ | 1 |
| Ehsan, Z | 1 |
| Montgomery, GS | 1 |
| Tiller, C | 1 |
| Kisling, J | 1 |
| Chang, DV | 1 |
| Tepper, RS | 1 |
| Christensen, CC | 1 |
| Ryg, MS | 1 |
| Refvem, OK | 1 |
| Skjønsberg, OH | 1 |
| Zheng, J | 1 |
| Pan, M | 1 |
| Ding, X | 1 |
| Deng, W | 1 |
| Anderson, P | 1 |
| Höglund, M | 1 |
| Rödjer, S | 1 |
| Miller, A | 1 |
| Brown, LK | 1 |
| Pastores, GM | 1 |
| Desnick, RJ | 1 |
| Yoshioka, Y | 1 |
| Saiki, S | 1 |
| Tsutsumi-Ishii, Y | 1 |
| Koyama, R | 1 |
| Hirashima, N | 1 |
| Harada, N | 1 |
| Yamasaki, S | 1 |
| Suda, K | 1 |
| Fukuchi, Y | 1 |
| Hesselstrand, R | 1 |
| Ekman, R | 1 |
| Eskilsson, J | 1 |
| Isaksson, A | 1 |
| Scheja, A | 1 |
| Ohlin, AK | 1 |
| Akesson, A | 1 |
| Kadota, J | 1 |
| Mizunoe, S | 1 |
| Mito, K | 1 |
| Mukae, H | 1 |
| Yoshioka, S | 1 |
| Kawakami, K | 1 |
| Koguchi, Y | 1 |
| Fukushima, K | 1 |
| Kon, S | 1 |
| Kohno, S | 1 |
| Saito, A | 1 |
| Uede, T | 1 |
| Nasu, M | 1 |
| Kawut, SM | 1 |
| O'Shea, MK | 1 |
| Bartels, MN | 1 |
| Wilt, JS | 1 |
| Sonett, JR | 1 |
| van der Lee, I | 1 |
| Zanen, P | 1 |
| Snijder, RJ | 1 |
| van den Bosch, JMM | 1 |
| Aduen, JF | 1 |
| Zisman, DA | 1 |
| Mobin, SI | 1 |
| Venegas, C | 1 |
| Alvarez, F | 1 |
| Biewend, M | 1 |
| Jolles, HI | 1 |
| Keller, CA | 1 |
| Tiev, KP | 1 |
| Cabane, J | 1 |
| Aubourg, F | 1 |
| Kettaneh, A | 1 |
| Ziani, M | 1 |
| Duong-Quy, S | 1 |
| Fajac, I | 1 |
| Guillevin, L | 2 |
| Dinh-Xuan, AT | 1 |
| Pagnoux, C | 1 |
| Queyrel, V | 1 |
| Quadrelli, S | 1 |
| Ciallella, L | 1 |
| Catalán Pellet, AC | 1 |
| Molinari, L | 1 |
| Salvado, A | 1 |
| Auad, C | 1 |
| Spina, JC | 1 |
| Bankier, AA | 1 |
| Kiener, HP | 1 |
| Wiesmayr, MN | 1 |
| Fleischmann, D | 1 |
| Kontrus, M | 1 |
| Herold, CJ | 1 |
| Graninger, W | 1 |
| Hübsch, P | 1 |
| Baydur, A | 1 |
| Yuan, Y | 1 |
| Luo, Y | 1 |
| Zeng, J | 1 |
| He, T | 1 |
| Minai, OA | 1 |
| Sullivan, EJ | 1 |
| Stoller, JK | 1 |
| Nakajima, M | 1 |
| Kawahara, Y | 1 |
| Yoshida, K | 1 |
| Miyashita, N | 1 |
| Niki, Y | 1 |
| Matsushima, T | 1 |
| Hadeli, KO | 1 |
| Siegel, EM | 1 |
| Sherrill, DL | 1 |
| Beck, KC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cyclophosphamide Versus Placebo in Scleroderma Lung Study[NCT00004563] | Phase 3 | 158 participants (Actual) | Interventional | 1999-08-31 | Completed | ||
| Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)[NCT00883129] | Phase 2 | 142 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| A Randomized, Double Blind Controlled Trial Comparing Rituximab Against Intravenous Cyclophosphamide in Connective Tissue Disease Associated Interstitial Lung Disease[NCT01862926] | Phase 2/Phase 3 | 104 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
| Changes in Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide After Allogeneic Versus Autologous Hematopoietic Stem-cell Transplantation[NCT01735526] | 40 participants (Actual) | Observational | 2012-10-31 | Completed | |||
| Comparison of Upper and Lower Limb Maximal Exercise Capacities, Muscle Oxygenation and Energy Consumption During Tests in Patients With Interstitial Lung Disease[NCT06141603] | 30 participants (Anticipated) | Observational | 2023-11-25 | Recruiting | |||
| Comparison of Different Functional Tests and Relation With Functional State and Quality of Life in Individuals With Chronic Obstructive Pulmonary Disease (COPD)[NCT00660738] | 11 participants (Actual) | Observational | 2007-01-31 | Completed | |||
| Reproducibility of 6 Minute Walk Tests for Oxygen Desaturation[NCT00740220] | 97 participants (Actual) | Observational | 2006-09-30 | Completed | |||
| Evaluation of Reliability, Sensitivity and Validity of the Six Minute Step Test in Patients With Chronic Obstructive Pulmonary Disease and Its Relation With Predictors Markers of Risk of Death[NCT01298661] | 91 participants (Actual) | Interventional | 2011-02-28 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
diffusing capacity of the lungs for carbon monoxide (NCT00004563)
Timeframe: 12 months
| Intervention | % of predicted (Mean) |
|---|---|
| Cylophosphamide | 42.8 |
| Placebo | 44.3 |
The primary end point was the forced vital capacity (FVC, expressed as a percentage of the predicted value) at 12 months, after adjustment for the baseline FVC. (NCT00004563)
Timeframe: 12 months
| Intervention | % of predicted (Mean) |
|---|---|
| Cylophosphamide | 66.6 |
| Placebo | 65.6 |
expressed as a percentage of the predicted value (NCT00004563)
Timeframe: 12 months
| Intervention | % of predicted (Mean) |
|---|---|
| Cylophosphamide | 70.5 |
| Placebo | 64.7 |
Imaging of the whole lung (WL) is performed using a volumetric high resolution computerized tomography (HRCT) scan, which is then analyzed using a computer algorithm to determine the percentage of overall pixels exhibiting features characteristic for quantitative lung fibrosis (QLF). Higher percentages for QLF-WL therefore represent greater involvement by lung fibrosis. (NCT00883129)
Timeframe: Measured at baseline and Month 24
| Intervention | % of lung exhibiting QLF (Mean) | |
|---|---|---|
| Baseline | Month 24 | |
| Cyclophosphamide Arm | 8.91 | 8.48 |
| Mycophenolate Arm | 8.25 | 7.99 |
The primary outcome is the course over time from baseline to 24 months for the FVC %-predicted. The FVC %-predicted represents the adjusted volume of air (adjusted as a percentage of the expected normal valued based on the participant's age, height, gender and ethnicity) that can be forcibly exhaled from the lungs after taking the deepest breath possible. The FVC %-predicted is reduced in patients with interstitial lung disease and is used as a measure of lung involvement and disease severity. (NCT00883129)
Timeframe: Measured at study Baseline and Months 3, 6, 12, 15, 18, 21, and 24
| Intervention | FVC %-pred (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Month 3 | Month 6 | Month 9 | Month 12 | Month 15 | Month 18 | Month 21 | Month 24 | |
| Cyclophosphamide Arm | 66.52 | 67.03 | 67.86 | 69.42 | 69.86 | 71.94 | 72.57 | 72.55 | 70.15 |
| Mycophenolate Arm | 66.52 | 66.22 | 68.02 | 68.11 | 68.43 | 69.84 | 70.57 | 70.87 | 69.65 |
The HAQ-DI asks questions related to 8 activity domains (dressing, arising, eating, walking, hygiene, reach, grip, and common daily activities) with the patient's capacity to carry out each activity scored from 0 to 3. Scores across all domains are averaged and a higher score represents greater disability. (NCT00883129)
Timeframe: Measured at study entry and Months 3, 6, 9, 12, 15, 18, 21, and 24
| Intervention | HAQ-DI Total Score (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Month 3 | Month 6 | Month 9 | Month 12 | Month 15 | Month 18 | Month 21 | Month 24 | |
| Cyclophosphamide Arm | 0.74 | 0.64 | 0.58 | 0.65 | 0.56 | 0.62 | 0.55 | 0.48 | 0.57 |
| Mycophenolate Arm | 0.71 | 0.83 | 0.75 | 0.66 | 0.64 | 0.58 | 0.55 | 0.65 | 0.62 |
The DLCO is a pulmonary function test that measures the capacity for the lung to carry out gas exchange between the inhaled breath and the pulmonary capillary blood vessels and the DLCO %-predicted represents the DLCO expressed as a percentage of the expected normal valued based on the participant's age, height, gender and ethnicity. The DLCO %-predicted is reduced in patients with interstitial lung disease and is used as a measure of disease severity. (NCT00883129)
Timeframe: Measured at study entry and Months 3, 6, 12, 15, 18, 21, and 24
| Intervention | DLCO %-pred (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Month 3 | Month 6 | Month 9 | Month 12 | Month 15 | Month 18 | Month 21 | Month 24 | |
| Cyclophosphamide Arm | 54.05 | 51.92 | 50.87 | 51.55 | 53.12 | 53.62 | 55.9 | 54.26 | 52.90 |
| Mycophenolate Arm | 53.99 | 53.38 | 54.86 | 54.13 | 55.32 | 57.77 | 56.62 | 55.47 | 55.31 |
Skin thickness is quantified using the modified Rodnan measurement method (mRSS), with a scale that ranges from 0 (no skin involvement) to a maximum of 51. The reported skin score is determined by a clinical assessment of skin thickness, which is performed by a trained reader, and represents the sum of individual assessments that are made in each of 17 body areas. Each area is given a score in the range of 0-3 (0 = normal; 1= mild thickness; 2 = moderate; 3 = severe thickness). A higher score represents more severe skin involvement. (NCT00883129)
Timeframe: Measured at baseline and Months 3, 6, 9, 12, 15, 18, 21, and 24
| Intervention | mRSS score (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Month 3 | Month 6 | Month 9 | Month 12 | Month 15 | Month 18 | Month 21 | Month 24 | |
| Cyclophosphamide Arm | 14.04 | 12.85 | 11.95 | 10.61 | 9.47 | 9.80 | 9.87 | 8.50 | 7.87 |
| Mycophenolate Arm | 15.32 | 16.03 | 14.37 | 14.33 | 12.45 | 12.43 | 11.98 | 11.22 | 11.40 |
The number of participants who remained in the study at the listed time points are reported (NCT00883129)
Timeframe: Continuous assessment from randomization to 24 months
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Month 3 | Month 6 | Month 9 | Month 12 | Month 15 | Month 18 | Month 21 | Month 24 | |
| Cyclophosphamide Arm | 73 | 64 | 56 | 51 | 46 | 44 | 42 | 39 | 38 |
| Mycophenolate Arm | 69 | 66 | 58 | 55 | 52 | 52 | 49 | 49 | 49 |
The TLC represents the total volume of air within the lung after taking the deepest breath possible and the TLC %-predicted represents the TLC expressed as a percentage of the expected normal valued based on the participant's age, height, gender and ethnicity. The TLC %-predicted is reduced in patients with interstitial lung disease and is used as a measure of disease severity. (NCT00883129)
Timeframe: Measured at study entry and Months 6, 12, 18, and 24
| Intervention | TLC %-pred (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Month 6 | Month 12 | Month 18 | Month 24 | |
| Cyclophosphamide Arm | 65.49 | 67.39 | 68.25 | 69.63 | 66.97 |
| Mycophenolate Arm | 66.16 | 67.84 | 67.31 | 68.50 | 68.24 |
(NCT00883129)
Timeframe: Measured throughout the 2-year study
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Leukopenia (<2.5x10^3 WBC/microliter) | Neutropenia (<1.0x10^3 neutrophils/microliter) | Anemia (Hgb <10 g/dl) | Thrombocytopenia (<100x10^3 platelets/microliter) | Hematuria (>10 RBC/high power field) | Pneumonia | SAE-Total | SAE-related to treatment | Deaths | |
| Cyclophosphamide Arm | 30 | 7 | 13 | 4 | 2 | 4 | 22 | 7 | 11 |
| Mycophenolate Arm | 4 | 3 | 8 | 0 | 3 | 5 | 27 | 3 | 5 |
Change in breathlessness was assessed using the Transitional Dyspnea Index, which compares current symptoms to those at baseline. Total score ranges from - 9 to + 9. The lower the score, the more deterioration in severity of dyspnea. (NCT00883129)
Timeframe: Measured at Months 6, 12, 18, and 24
| Intervention | Transitional Dyspnea Index Score (Mean) | |||
|---|---|---|---|---|
| Month 6 | Month 12 | Month 18 | Month 24 | |
| Cyclophosphamide Arm | 0.31 | 1.23 | 1.78 | 2.09 |
| Mycophenolate Arm | 0.74 | 1.17 | 0.91 | 1.86 |
The kappa statistic is a measure of the quality of a test. It is a ratio. (NCT00740220)
Timeframe: All three 6MWTs should take place within 30 days
| Intervention | Ratio (Number) |
|---|---|
| Single Arm Prospective Observational Study | 0.62 |
"It was evaluated only in the COPD patients. BODE index is a prognostic index used in COPD patients, it is a 0-10 scale, where lower values means better prognostic. It is composed by other commonly used evaluations tools in COPD, Forced Expiratory Volume in the First second (from spirometry); classification in the scale ranging from 0-3, Body-mass index, classification in the scale ranging from 0-1; Six-minute walk test distance, classification in the scale ranging from 0-3 and referred dyspnea, classification in the scale ranging from 0-3.~It was only used the total score (0-10)" (NCT01298661)
Timeframe: Second day
| Intervention | units on a scale (Median) |
|---|---|
| COPD Patients | 3 |
"This test will be conducted by the Rater 1, the patient will step up and down one 20cm step during six minute. The Exertion Perception will be evaluated using BORG scale. This scale is a self-reported scale, which range from 0 to 10, where 0 means none exertion perception and 10 means very intense exertion perception (the highest the patient has ever felt). Lower values means that the patient feel less discomfort." (NCT01298661)
Timeframe: First day or second day of the protocol (random)
| Intervention | units on a scale (Median) |
|---|---|
| Healthy Young Subjects | 2 |
| Healthy Elderly Subjects | 2.5 |
| COPD Patients | 2 |
"This test will be conducted by the Rater 1, the patient will step up and down a 20cm step during six minute. It will be evaluated by a cardio monitor." (NCT01298661)
Timeframe: First day or second day of the protocol (random)
| Intervention | bpm (Mean) |
|---|---|
| Healthy Young Subjects | 154 |
| Healthy Elderly Subjects | 116 |
| COPD Patients | 117 |
"This test will be conducted by the Rater 1, the patient will step up and down a 20cm step during six minute. The performance will be evaluated by the number of the steps." (NCT01298661)
Timeframe: First day or second day of the protocol (random)
| Intervention | steps (Mean) |
|---|---|
| Healthy Young Subjects | 166.4 |
| Healthy Elderly Subjects | 114.0 |
| COPD Patients | 76.6 |
"This test will be conducted by the Rater 1, the patient will step up and down one 20cm step during six minute. It will be evaluated by a pulse oxymeter." (NCT01298661)
Timeframe: First day or second day of the protocol (random)
| Intervention | % of hemoglobin (Mean) |
|---|---|
| Healthy Young Subjects | 95.8 |
| Healthy Elderly Subjects | 95 |
| COPD Patients | 90.1 |
"This test will be conducted by the Rater 1, the subject will walk as far as it can in a 30m corridor during 6 minutes. The performance will be the distance (meters)that it walk." (NCT01298661)
Timeframe: First day or second day of the protocol (random)
| Intervention | meter (Mean) |
|---|---|
| Healthy Young Subjects | 643.5 |
| Healthy Elderly Subjects | 504.5 |
| COPD Patients | 380.4 |
"This test was conducted by the Rater 1, the subject walked as far as it could in a 30m corridor during 6 minutes. The Exertion Perception will be evaluated using BORG scale. This scale is a self-reported scale, which range from 0 to 10, where 0 means none exertion perception and 10 means very intense exertion perception (the highest the patient has ever felt). Lower values means that the patient feel less discomfort." (NCT01298661)
Timeframe: First day or second day of the protocol (random)
| Intervention | units on a scale (Median) |
|---|---|
| Healthy Young Subjects | 1 |
| Healthy Elderly Subjects | 0.5 |
| COPD Patients | 1 |
"This test will be conducted by the Rater 1, the subject will walk as far as it can in a 30m corridor during 6 minutes. It will be evaluated by a cardio monitor." (NCT01298661)
Timeframe: First day or second day of the protocol (random)
| Intervention | bpm (Mean) |
|---|---|
| Healthy Young Subjects | 143 |
| Healthy Elderly Subjects | 115 |
| COPD Patients | 113 |
"This test will be conducted by the Rater 1, the subject will walk as far as it can in a 30m corridor during 6 minutes. It will be evaluated by a pulse oxymeter." (NCT01298661)
Timeframe: First day or second day of the protocol (random)
| Intervention | % of hemoglobin (Mean) |
|---|---|
| Healthy Young Subjects | 96.7 |
| Healthy Elderly Subjects | 94.5 |
| COPD Patients | 90.4 |
"This test will be conducted by the Rater 1, the patient will step up and down one 20cm step during six minute.The Exertion Perception will be evaluated using BORG scale. This scale is a self-reported scale, which range from 0 to 10, where 0 means none exertion perception and 10 means very intense exertion perception (the highest the patient has ever felt). Lower values means that the patient feel less discomfort." (NCT01298661)
Timeframe: First day or second day of the protocol (random), 30 minutes after the first 6MST
| Intervention | units on a scale (Median) |
|---|---|
| Healthy Young Subjects | 2 |
| Healthy Elderly Subjects | 1.5 |
| COPD Patients | 2.5 |
"This test will be conducted by the Rater 1, the patient will step up and down a 20cm step during six minute. It will be evaluated by a cardio monitor." (NCT01298661)
Timeframe: First day or second day of the protocol (random), 30 minutes after the first 6MST
| Intervention | bpm (Mean) |
|---|---|
| Healthy Young Subjects | 159 |
| Healthy Elderly Subjects | 118 |
| COPD Patients | 117 |
"This test will be conducted by the Rater 1, the patient will step up and down a 20cm step during six minutes. The performance will be evaluated by the number of the climbs." (NCT01298661)
Timeframe: On the first or second day of evaluation (random), 30 minutes after the first 6MST.
| Intervention | steps (Mean) |
|---|---|
| Healthy Young Subjects | 170.7 |
| Healthy Elderly Subjects | 114.5 |
| COPD Patients | 82.4 |
"This test will be conducted by the Rater 1, the patient will step up and down one 20cm step during six minute. It will be evaluated by a pulse oxymeter ." (NCT01298661)
Timeframe: First day or second day of the protocol (random) ,30 minutes after the first 6MST
| Intervention | % of hemoglobin (Mean) |
|---|---|
| Healthy Young Subjects | 96 |
| Healthy Elderly Subjects | 94.9 |
| COPD Patients | 90.5 |
"This test will be conducted by the Rater 1, the subject will walk as far as it can in a 30m corridor during 6 minutes. The performance will be the distance (meters)that it walk." (NCT01298661)
Timeframe: On the first or second day of evaluation (random), 30 minutes after the first 6MWT.
| Intervention | meter (Mean) |
|---|---|
| Healthy Young Subjects | 648.2 |
| Healthy Elderly Subjects | 513.6 |
| COPD Patients | 391.0 |
"This test will be conducted by the Rater 1, the subject will walk as far as it can in a 30m corridor during 6 minutes. The Exertion Perception will be evaluated using BORG scale. This scale is a self-reported scale, which range from 0 to 10, where 0 means none exertion perception and 10 means very intense exertion perception (the highest the patient has ever felt). Lower values means that the patient feel less discomfort." (NCT01298661)
Timeframe: First day or second day of the protocol (random), 30 minutes after the first 6MWT
| Intervention | units on a scale (Median) |
|---|---|
| Healthy Young Subjects | 0.5 |
| Healthy Elderly Subjects | 0.5 |
| COPD Patients | 1 |
"This test will be conducted by the Rater 1, the subject will walk as far as it can in a 30m corridor during 6 minutes. It will be evaluated by a cardio monitor at rest and every two minutes of the test." (NCT01298661)
Timeframe: First day or second day of the protocol (random), 30 minutes after the first 6MWT
| Intervention | bpm (Mean) |
|---|---|
| Healthy Young Subjects | 144 |
| Healthy Elderly Subjects | 115 |
| COPD Patients | 112 |
"This test will be conducted by the Rater 1, the subject will walk as far as it can in a 30m corridor during 6 minutes. It will be evaluated by a pulse oxymeter." (NCT01298661)
Timeframe: ,First day or second day of the protocol (random) 30 minutes after the first 6MWT
| Intervention | % of hemoglobin (Mean) |
|---|---|
| Healthy Young Subjects | 96.4 |
| Healthy Elderly Subjects | 95.1 |
| COPD Patients | 90.3 |
"This test will be conducted by the Rater 2, the patient will step up down one 20cm step during six minute. The Exertion Perception will be evaluated using BORG scale. This scale is a self-reported scale, which range from 0 to 10, where 0 means none exertion perception and 10 means very intense exertion perception (the highest the patient has ever felt). Lower values means that the patient feel less discomfort." (NCT01298661)
Timeframe: On the third day of evaluation, seven days after the first day of evaluation. Since it was performed in the same day of the third 6MWT, the choice of the first test was random, and there was a 30 minute interval between them.
| Intervention | units on a scale (Median) |
|---|---|
| Healthy Young Subjects | 1 |
| Healthy Elderly Subjects | 2 |
| COPD Patients | 2.5 |
"This test will be conducted by the Rater 2, the patient will step up and down a 20cm step during six minute. It will be evaluated by a cardio monitor." (NCT01298661)
Timeframe: On the third day of evaluation, seven days after the first day of evaluation. Since it was performed in the same day of the third 6MWT, the choice of the first test was random, and there was a 30 minute interval between them.
| Intervention | bpm (Mean) |
|---|---|
| Healthy Young Subjects | 156 |
| Healthy Elderly Subjects | 117 |
| COPD Patients | 116 |
"This test will be conducted by the Rater 2, the patient will step up and down a 20cm step during six minutes. The performance will be evaluated by the number of the climbs." (NCT01298661)
Timeframe: On the third day of evaluation, seven days after the first day of evaluation. Since it was performed in the same day of the third 6MWT, the choice of the first test was random, and there was a 30 minute interval between them.
| Intervention | steps (Mean) |
|---|---|
| Healthy Young Subjects | 172.3 |
| Healthy Elderly Subjects | 111.3 |
| COPD Patients | 86.4 |
"This test will be conducted by the Rater 2, the patient will step up and down one 20cm step during six minute. It will be evaluated by a pulse oxymeter." (NCT01298661)
Timeframe: On the third day of evaluation, seven days after the first day of evaluation. Since it was performed in the same day of the third 6MWT, the choice of the first test was random, and there was a 30 minute interval between them.
| Intervention | % of hemoglobin (Mean) |
|---|---|
| Healthy Young Subjects | 95.8 |
| Healthy Elderly Subjects | 94.9 |
| COPD Patients | 90.3 |
"This test will be conducted by the Rater 2, the subject will walk as far as it can in a 30m corridor during 6 minutes. The performance will be the distance (meters)that it walk." (NCT01298661)
Timeframe: On the third day of evaluation, seven days after the first day of evaluation. Since it was performed in the same day of the third 6MST, the choice of the first test was random, and there was a 30 minute interval between them.
| Intervention | meter (Mean) |
|---|---|
| Healthy Young Subjects | 648.3 |
| Healthy Elderly Subjects | 502 |
| COPD Patients | 392.4 |
"This test will be conducted by the Rater 2, the subject will walk as far as it can in a 30m corridor during 6 minutes. The Exertion Perception will be evaluated using BORG scale. This scale is a self-reported scale, which range from 0 to 10, where 0 means none exertion perception and 10 means very intense exertion perception (the highest the patient has ever felt). Lower values means that the patient feel less discomfort." (NCT01298661)
Timeframe: On the third day of evaluation, seven days after the first day of evaluation. Since it was performed in the same day of the third 6MST, the choice of the first test was random, and there was a 30 minute interval between them.
| Intervention | units on a scale (Median) |
|---|---|
| Healthy Young Subjects | 1 |
| Healthy Elderly Subjects | 1 |
| COPD Patients | 2 |
"This test will be conducted by the Rater 2, the subject will walk as far as it can in a 30m corridor during 6 minutes. It will be evaluated by a cardio monitor." (NCT01298661)
Timeframe: On the third day of evaluation, seven days after the first day of evaluation. Since it was performed in the same day of the third 6MST, the choice of the first test was random, and there was a 30 minute interval between them.
| Intervention | bpm (Mean) |
|---|---|
| Healthy Young Subjects | 145 |
| Healthy Elderly Subjects | 112 |
| COPD Patients | 114 |
"This test will be conducted by the Rater 2, the subject will walk as far as it can in a 30m corridor during 6 minutes. It will be evaluated by a pulse oxymeter." (NCT01298661)
Timeframe: On the third day of evaluation, seven days after the first day of evaluation. Since it was performed in the same day of the third 6MST, the choice of the first test was random, and there was a 30 minute interval between them.
| Intervention | % of hemoglobin (Mean) |
|---|---|
| Healthy Young Subjects | 96.1 |
| Healthy Elderly Subjects | 94.7 |
| COPD Patients | 89.7 |
6 reviews available for carbon monoxide and Diffuse Parenchymal Lung Disease
| Article | Year |
|---|---|
Predictors of progression in systemic sclerosis patients with interstitial lung disease.
Topics: Biomarkers; Carbon Monoxide; Disease Progression; Humans; Lung; Lung Diseases, Interstitial; Respira | 2020 |
Office-based DLCO tests help pulmonologists to make important clinical decisions.
Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Female; Follow-Up Studies; Humans; Lung Diseases, I | 2016 |
Diffusing capacity.
Topics: Carbon Monoxide; Diffusion; Evaluation Studies as Topic; Humans; Lung; Lung Diseases, Interstitial; | 2009 |
[Early diagnosis of connective tissue disease-related pulmonary hypertension].
Topics: Biomarkers; Carbon Monoxide; Chronic Disease; Connective Tissue Diseases; Early Diagnosis; Echocardi | 2009 |
Pulmonary physiology in interstitial lung disease: recent developments in diagnostic and prognostic implications.
Topics: Airway Resistance; Biopsy; Bronchoalveolar Lavage Fluid; Carbon Monoxide; Female; Forced Expiratory | 1996 |
Pulmonary involvement in Niemann-Pick disease: case report and literature review.
Topics: Carbon Monoxide; Diffusion; Female; Humans; Lung Diseases, Interstitial; Middle Aged; Niemann-Pick D | 2000 |
3 trials available for carbon monoxide and Diffuse Parenchymal Lung Disease
| Article | Year |
|---|---|
Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.
Topics: Adult; Carbon Monoxide; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Female; | 2019 |
Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis.
Topics: Adult; Carbon Monoxide; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Multivariate | 2016 |
Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis.
Topics: Adult; Carbon Monoxide; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Multivariate | 2016 |
Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis.
Topics: Adult; Carbon Monoxide; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Multivariate | 2016 |
Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis.
Topics: Adult; Carbon Monoxide; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Multivariate | 2016 |
High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study.
Topics: Adult; Carbon Monoxide; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Glucocorticoids; | 2009 |
71 other studies available for carbon monoxide and Diffuse Parenchymal Lung Disease
| Article | Year |
|---|---|
Risk Factors Associated with Impairment in Pulmonary Diffusing Capacity among Patients with Noncystic Fibrosis Bronchiectasis.
Topics: Bronchiectasis; Carbon Monoxide; Fibrosis; Humans; Lung Diseases, Interstitial; Pulmonary Diffusing | 2022 |
Anti-vinculin antibodies as a novel biomarker in Egyptian patients with systemic sclerosis.
Topics: Autoantibodies; Biomarkers; Carbon Monoxide; Egypt; Female; Humans; Lung Diseases, Interstitial; Mal | 2022 |
Interstitial lung disease in patients with systemic lupus erythematosus: a cohort study.
Topics: Carbon Monoxide; Cohort Studies; Humans; Hydroxychloroquine; Lung; Lung Diseases, Interstitial; Lupu | 2022 |
Association Between Interstitial Lung Disease and Outcomes After Lung Cancer Resection.
Topics: Carbon Monoxide; Carcinoma, Non-Small-Cell Lung; Humans; Lung; Lung Diseases, Interstitial; Lung Neo | 2023 |
[Rebreathing method for measuring CO transfer factor in children].
Topics: Adolescent; Carbon Monoxide; Case-Control Studies; Child; Child, Preschool; Female; Humans; Lung Dis | 2019 |
Clinical Characteristics and Natural History of Autoimmune Forms of Interstitial Lung Disease: A Single-Center Experience.
Topics: Adult; Age Distribution; Age Factors; Aged; Arthritis, Rheumatoid; Autoimmune Diseases; Carbon Monox | 2019 |
Lung function is associated with minimal EQ-5D changes over time in patients with systemic sclerosis.
Topics: Adult; Aged; Carbon Monoxide; Female; Humans; Lung; Lung Diseases, Interstitial; Male; Middle Aged; | 2020 |
Beneficial impact of weight loss on respiratory function in interstitial lung disease patients with obesity.
Topics: Adult; Aged; Body Mass Index; Carbon Monoxide; Female; Follow-Up Studies; Functional Residual Capaci | 2021 |
Increased Levels of Soluble CD206 Associated with Rapidly Progressive Interstitial Lung Disease in Patients with Dermatomyositis.
Topics: Adult; Autoantibodies; Biomarkers; Carbon Monoxide; Case-Control Studies; Dermatomyositis; Diffusion | 2020 |
Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study.
Topics: Adult; Aged; C-Reactive Protein; Carbon Monoxide; Case-Control Studies; Cross-Sectional Studies; Cyc | 2021 |
Assessing the applicability of the new Global Lung Function Initiative reference values for the diffusing capacity of the lung for carbon monoxide in a large population set.
Topics: Adult; Aged; Asthma; Bronchitis; Carbon Monoxide; Cystic Fibrosis; Female; Humans; Lung; Lung Diseas | 2021 |
The effects of carbon monoxide releasing molecules on paraquat-induced pulmonary interstitial inflammation and fibrosis.
Topics: Animals; Boranes; Carbon Monoxide; Carbonates; Cell Line; Cell Survival; Dose-Response Relationship, | 2021 |
Performance of Lung Ultrasound for Monitoring Interstitial Lung Disease.
Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Female; Humans; Lung; Lung Diseases, Interstitial; | 2022 |
Cardiopulmonary exercise factors predict survival in patients with advanced interstitial lung disease referred for lung transplantation.
Topics: Aged; Carbon Monoxide; Cross-Sectional Studies; Exercise Test; Exercise Tolerance; Female; Humans; L | 2017 |
Understanding the determinants of health-related quality of life in rheumatoid arthritis-associated interstitial lung disease.
Topics: Aged; Arthritis, Rheumatoid; Carbon Monoxide; Cohort Studies; Dyspnea; Female; Forced Expiratory Vol | 2017 |
The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.
Topics: Aged; Arthritis, Rheumatoid; Carbon Monoxide; Female; Health Status Indicators; Humans; Idiopathic P | 2017 |
Novel Assessment of Interstitial Lung Disease Using the "Computer-Aided Lung Informatics for Pathology Evaluation and Rating" (CALIPER) Software System in Idiopathic Inflammatory Myopathies.
Topics: Adult; Aged; Carbon Monoxide; Cohort Studies; Female; Humans; Image Processing, Computer-Assisted; I | 2017 |
Correlation of pulmonary function and usual interstitial pneumonia computed tomography patterns in idiopathic pulmonary fibrosis.
Topics: Aged; Aged, 80 and over; Carbon Monoxide; Disease Progression; Female; Humans; Idiopathic Pulmonary | 2017 |
Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carbon Monoxide; Cyclophosphamide; Diffusion; Echocardio | 2017 |
Exertional hypoxemia is more severe in fibrotic interstitial lung disease than in COPD.
Topics: Aged; Carbon Monoxide; Exercise Test; Female; Humans; Hypoxia; Lung Diseases, Interstitial; Male; Mi | 2018 |
Unclassifiable-interstitial lung disease: Outcome prediction using CT and functional indices.
Topics: Aged; Bronchiectasis; Carbon Monoxide; Connective Tissue Diseases; Female; Forced Expiratory Volume; | 2017 |
Thin-section computed tomography-determined usual interstitial pneumonia pattern affects the decision-making process for resection in newly diagnosed lung cancer patients: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Clinical Decision-Making; Female; Humans; Lung Dise | 2018 |
Emphysematous change with scleroderma-associated interstitial lung disease: the potential contribution of vasculopathy?
Topics: Aged; Carbon Monoxide; Female; Forced Expiratory Volume; Humans; Lung; Lung Diseases, Interstitial; | 2018 |
Physiological predictors of Hypoxic Challenge Testing (HCT) outcomes in Interstitial Lung Disease (ILD).
Topics: Aerospace Medicine; Aged; Aircraft; Algorithms; Carbon Monoxide; Female; Humans; Hypoxia; Idiopathic | 2018 |
Nailfold Videocapillaroscopy Changes Are Associated With the Presence and Severity of Systemic Sclerosis-Related Interstitial Lung Disease.
Topics: Adult; Aged; Capillaries; Carbon Monoxide; Female; Humans; Lung Diseases, Interstitial; Male; Micros | 2019 |
Rising stars of DPLD survival: FVC and exercise desaturation (a single-center study)
Topics: Age Factors; Aged; Blood Pressure; Carbon Monoxide; Connective Tissue Diseases; Exercise; Exercise T | 2018 |
Survival in pulmonary hypertension due to chronic lung disease: Influence of low diffusion capacity of the lungs for carbon monoxide.
Topics: Aged; Carbon Monoxide; Chronic Disease; Female; Follow-Up Studies; Forced Expiratory Volume; Humans; | 2019 |
Comparison of clinical courses and mortality of connective tissue disease-associated interstitial pneumonias and chronic fibrosing idiopathic interstitial pneumonias.
Topics: Aged; Carbon Monoxide; Disease Progression; Female; Forced Expiratory Volume; Humans; Idiopathic Int | 2019 |
Clinical significance of autoantibody positivity in idiopathic pulmonary fibrosis.
Topics: Aged; Antibodies, Antineutrophil Cytoplasmic; Autoantibodies; Carbon Monoxide; Female; Glucocorticoi | 2019 |
Comparison of different measures of diffusing capacity for carbon monoxide (DLCO) in systemic sclerosis.
Topics: Aged; Carbon Monoxide; Cohort Studies; Female; Humans; Hypertension, Pulmonary; Lung; Lung Diseases, | 2013 |
Predictors of exercise-induced oxygen desaturation in systemic sclerosis patients with interstitial lung disease.
Topics: Aged; Area Under Curve; Carbon Monoxide; Exercise Test; Female; Forced Expiratory Volume; Humans; Lu | 2014 |
Relevance of partitioning DLCO to detect pulmonary hypertension in systemic sclerosis.
Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Female; Humans; Hypertension, Pulmonary; Lung Disea | 2013 |
[Single-breath and rebreathing methods for measurement of pulmonary diffusing function: a comparative study].
Topics: Adult; Aged; Carbon Monoxide; Female; Humans; Lung; Lung Diseases, Interstitial; Male; Middle Aged; | 2013 |
Prevalence and evolution of scleroderma pattern at nailfold videocapillaroscopy in systemic sclerosis patients: Clinical and prognostic implications.
Topics: Adult; Aged; Autoantibodies; Capillaries; Carbon Monoxide; Diffusion; Female; Fingers; Follow-Up Stu | 2015 |
Different KCO and VA combinations exist for the same DLCO value in patients with diffuse parenchymal lung diseases.
Topics: Aged; Airway Obstruction; Carbon Monoxide; Cross-Sectional Studies; Female; Humans; Lung; Lung Disea | 2015 |
Diffusing Pulmonary Capacity Measured During Effort: A Possible Early Marker of Pulmonary Involvement In Systemic Sclerosis.
Topics: Biomarkers; Carbon Monoxide; Case-Control Studies; Exercise Test; Female; Humans; Lung Diseases, Int | 2015 |
Elevated Erythrocyte Sedimentation Rate Is Predictive of Interstitial Lung Disease and Mortality in Dermatomyositis: a Korean Retrospective Cohort Study.
Topics: Adult; Asian People; Blood Sedimentation; Carbon Monoxide; Cohort Studies; Dermatomyositis; Disease | 2016 |
Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline.
Topics: Adult; Aged; Antibodies, Antinuclear; Autoantibodies; Biomarkers; Carbon Monoxide; Female; Follow-Up | 2015 |
Pseudoxanthoma Elasticum - Also a Lung Disease? The Respiratory Affection of Patients with Pseudoxanthoma Elasticum.
Topics: Adult; Aged; Carbon Monoxide; Case-Control Studies; Cross-Sectional Studies; Female; Forced Expirato | 2016 |
Clinical features and natural history of interstitial pneumonia with autoimmune features: A single center experience.
Topics: Adrenal Cortex Hormones; Adult; Amino Acyl-tRNA Synthetases; Antibodies, Antinuclear; Autoimmune Dis | 2016 |
Clinical characteristics in patients with asymmetric idiopathic pulmonary fibrosis.
Topics: Aged; Biopsy; Carbon Monoxide; Case-Control Studies; Disease Progression; Female; Forced Expiratory | 2016 |
Prognostic determinants among clinical, thin-section CT, and histopathologic findings for fibrotic idiopathic interstitial pneumonias: tertiary hospital study.
Topics: Bronchoalveolar Lavage Fluid; Carbon Monoxide; Female; Fibrosis; Humans; Lung Diseases, Interstitial | 2008 |
T-cell activation profiles in different granulomatous interstitial lung diseases--a role for CD8+CD28(null) cells?
Topics: Adrenal Cortex Hormones; Adult; Aged; Alveolitis, Extrinsic Allergic; Antigens, CD; Bronchoalveolar | 2010 |
Clinical and high resolution computed tomography characteristics of patients with rheumatoid arthritis lung disease.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Asian People; Bronchiectasis; Carbon Monoxide | 2009 |
Impaired lung compliance and DL,CO but no restrictive ventilatory defect in sarcoidosis.
Topics: Adult; Carbon Monoxide; Female; Humans; Lung; Lung Compliance; Lung Diseases, Interstitial; Male; Mi | 2010 |
MRP14 is elevated in the bronchoalveolar lavage fluid of fibrosing interstitial lung diseases.
Topics: Adult; Aged; Biomarkers; Bronchoalveolar Lavage Fluid; Calgranulin B; Carbon Monoxide; Cell Count; F | 2010 |
Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease.
Topics: Adult; Aged; Antibodies, Antinuclear; Blood Pressure; Carbon Monoxide; Comorbidity; Cross-Sectional | 2011 |
Impaired carbon monoxide diffusing capacity as a marker of limited systemic sclerosis.
Topics: Adult; Aged; Biomarkers; Carbon Monoxide; Diagnosis, Differential; Diffusion; Female; Follow-Up Stud | 2011 |
Clinical significance of serum levels of secretory leukocyte protease inhibitor in patients with systemic sclerosis.
Topics: Biomarkers; Carbon Monoxide; Enzyme-Linked Immunosorbent Assay; Female; Humans; Lung; Lung Diseases, | 2012 |
Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Carbon Monoxide; Connective Tissue Diseases; Female; | 2012 |
Detection of interstitial lung disease in systemic sclerosis through partitioning of lung transfer for carbon monoxide.
Topics: Adult; Aged; Blood Volume; Breath Tests; Capillaries; Carbon Monoxide; Case-Control Studies; Female; | 2012 |
The pulmonary fibrosis-associated MUC5B promoter polymorphism does not influence the development of interstitial pneumonia in systemic sclerosis.
Topics: Adult; Aged; Carbon Monoxide; Case-Control Studies; Female; Genetic Predisposition to Disease; Genot | 2012 |
Respiratory muscle function in interstitial lung disease.
Topics: Aged; Anthropometry; Biomarkers; Carbon Monoxide; Case-Control Studies; Diaphragm; Exercise Test; Fe | 2013 |
An infant with pulmonary interstitial glycogenosis: clinical improvement is associated with improvement in the pulmonary diffusion capacity.
Topics: Breath Tests; Carbon Monoxide; Disease Progression; Forced Expiratory Volume; Glucocorticoids; Glyco | 2014 |
Effect of hypobaric hypoxia on blood gases in patients with restrictive lung disease.
Topics: Adult; Aged; Atmospheric Pressure; Blood Gas Analysis; Carbon Dioxide; Carbon Monoxide; Chronic Dise | 2002 |
Diagnosis of interstitial lung disease in patients with connective tissue disease by the diffusing capacity of carbon monoxide.
Topics: Carbon Monoxide; Connective Tissue Diseases; Humans; Lung Diseases, Interstitial; Radiography, Thora | 2002 |
Pulmonary side effects of interferon-alpha therapy in patients with hematological malignancies.
Topics: Adult; Aged; Autoimmunity; Carbon Monoxide; Female; Hematologic Neoplasms; Humans; Immunity, Cellula | 2003 |
Pulmonary involvement in type 1 Gaucher disease: functional and exercise findings in patients with and without clinical interstitial lung disease.
Topics: Adolescent; Adult; Biopsy; Carbon Monoxide; Citrates; Exercise; Exercise Test; Female; Gallium; Gauc | 2003 |
Adult-onset familial pulmonary fibrosis in Japanese brothers.
Topics: Adult; Carbon Monoxide; Consanguinity; DNA Mutational Analysis; Fatal Outcome; Female; Genetic Predi | 2004 |
Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001.
Topics: Age Factors; Blood Pressure; Calcitonin Gene-Related Peptide; Carbon Monoxide; Echocardiography, Dop | 2005 |
High plasma concentrations of osteopontin in patients with interstitial pneumonia.
Topics: Adult; Aged; Biomarkers; Carbon Monoxide; Female; Humans; Immunoenzyme Techniques; Lung Diseases, In | 2005 |
Exercise testing determines survival in patients with diffuse parenchymal lung disease evaluated for lung transplantation.
Topics: Adult; Carbon Monoxide; Cohort Studies; Exercise Test; Female; Humans; Lung Diseases, Interstitial; | 2005 |
Diffusing capacity for nitric oxide and carbon monoxide in patients with diffuse parenchymal lung disease and pulmonary arterial hypertension.
Topics: Adult; Carbon Monoxide; Female; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Male; | 2006 |
Retrospective study of pulmonary function tests in patients presenting with isolated reduction in single-breath diffusion capacity: implications for the diagnosis of combined obstructive and restrictive lung disease.
Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Dyspnea; Echocardiography; Female; Humans; Lung Dis | 2007 |
Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide.
Topics: Aged; Carbon Monoxide; Echocardiography; Female; Fibrosis; Humans; Lung Diseases; Lung Diseases, Int | 2007 |
Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease.
Topics: Adult; Carbon Monoxide; Comorbidity; Dyspnea; Female; Humans; Hypertension, Pulmonary; Lung Diseases | 2007 |
[Lung involvement in systemic sclerosis].
Topics: Adolescent; Adult; Aged; Biomarkers; Carbon Monoxide; Child; DNA Topoisomerases, Type I; Female; Hum | 2007 |
Discrete lung involvement in systemic lupus erythematosus: CT assessment.
Topics: Adult; Bronchial Diseases; Carbon Monoxide; Female; Forced Expiratory Volume; Humans; Lung Diseases; | 1995 |
[Diagnostic value of exercise diffusion capacity test on diffuse pulmonary fibrosis].
Topics: Adult; Carbon Monoxide; Exercise Test; Female; Humans; Lung; Lung Diseases, Interstitial; Lung Disea | 1996 |
Serum KL-6 as a possible marker for amiodarone-induced pulmonary toxicity.
Topics: Amiodarone; Anti-Arrhythmia Agents; Antigens; Antigens, Neoplasm; Biomarkers; Carbon Monoxide; Cardi | 2000 |
Predictors of oxygen desaturation during submaximal exercise in 8,000 patients.
Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Exercise Test; Female; Humans; Logistic Models; Lun | 2001 |
Predictors of oxygen desaturation during submaximal exercise in 8,000 patients.
Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Exercise Test; Female; Humans; Logistic Models; Lun | 2001 |
Predictors of oxygen desaturation during submaximal exercise in 8,000 patients.
Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Exercise Test; Female; Humans; Logistic Models; Lun | 2001 |
Predictors of oxygen desaturation during submaximal exercise in 8,000 patients.
Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Exercise Test; Female; Humans; Logistic Models; Lun | 2001 |
Predictors of oxygen desaturation during submaximal exercise in 8,000 patients.
Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Exercise Test; Female; Humans; Logistic Models; Lun | 2001 |
Predictors of oxygen desaturation during submaximal exercise in 8,000 patients.
Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Exercise Test; Female; Humans; Logistic Models; Lun | 2001 |
Predictors of oxygen desaturation during submaximal exercise in 8,000 patients.
Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Exercise Test; Female; Humans; Logistic Models; Lun | 2001 |
Predictors of oxygen desaturation during submaximal exercise in 8,000 patients.
Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Exercise Test; Female; Humans; Logistic Models; Lun | 2001 |
Predictors of oxygen desaturation during submaximal exercise in 8,000 patients.
Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Exercise Test; Female; Humans; Logistic Models; Lun | 2001 |